Following a Recent Pre-New Drug Application (NDA) Meeting with the FDA for UGN-101, the Company Has Concluded Patient Enrollment in the OLYMPUS Phase 3 Trial for Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Breakthrough Therapy Designation (BTD) Previously Granted by the FDA for UGN-101 for
RA’ANANA, Israel & NEW YORK --(BUSINESS WIRE)--Nov. 6, 2018-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018 : Stifel 2018 Healthcare Conference Tuesday, November 13 9:30AM Eastern Time New York, NY Jefferies 2018 London
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel & NEW YORK --(BUSINESS WIRE)--Nov. 5, 2018-- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018 , prior to the open of the market.
UGN-101 Joins Select Group of Urologic Oncology Product Candidates to Receive BTD On Track to Initiate Rolling Submission of UGN-101 New Drug Application (NDA) in Q4 2018 RA’ANANA, Israel & NEW YORK --(BUSINESS WIRE)--Oct. 30, 2018-- UroGen Pharma Ltd.
RA’ANANA, Israel & NEW YORK --(BUSINESS WIRE)--Sep. 25, 2018-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur , Chief Executive Officer,
Industry Veteran with Deep Scientific Expertise Will Focus on the Execution of Business Development Strategy RA’ANANA, Israel & NEW YORK --(BUSINESS WIRE)--Sep. 11, 2018-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones “Woody” Bryan, Ph.D.
Plan to Initiate Q4 2018 Rolling New Drug Application (NDA) Submission to the U.S. Food and Drug Administration ( FDA ) for UGN-101, Ahead of Initial Projection of Q1 2019 Initiated Phase 2b Clinical Trial of UGN-102 (VesiGel™) f or the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization RA’ANANA, Israel , and NEW YORK , Aug. 08, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK , Aug. 07, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report second quarter 2018 financial results on Tuesday, August 14, 2018 , prior to the open of the market.
Company Expects to Begin U.S. Phase 2b Clinical Trial in Q3 2018 UGN-102 Has Potential to Become the First Front Line Non-Surgical Therapy for Patients with LG NMIBC RA’ANANA, Israel and NEW YORK , July 11, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage
